Primary Hepatic Lymphoma: Role of Low-Dose Radiotherapy at a Single Institution with Genetic Characterization and Paired Literature Review

放射治疗 淋巴瘤 医学 肿瘤科 内科学
作者
Jennifer Ma,Rémy Daou,Josiane Bou Eid,Jisun Lee,B. Fregonese,Joe M El-Khoury,N. Ari Wijetunga,Harper Hubbeling,Kathryn R. Tringale,Emily S. Lebow,Reith Sarkar,Brandon S. Imber,Joachim Yahalom,Carla Hajj
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 11949-11950
标识
DOI:10.1182/blood-2022-162623
摘要

Purpose/Objective: Primary hepatic lymphomas (PHL) are an extremely rare form of non-Hodgkin Lymphoma (NHL) for which there are no established treatment guidelines, with available literature largely comprised of small case reports. Therefore, we evaluate our institutional experience treating PHL within the context of existing literature to better understand treatment modalities, role of radiotherapy (RT), and outcomes. Traditionally, radiotherapy for indolent lymphomas has involved treatment of up to 2400cGy in 12 fractions, however the use of low-dose radiotherapy of 400cGy in 1-2 fractions has been increasingly utilized. However to our knowledge, use of low-dose RT for liver lymphomas has not previously been reported in the literature. Materials/Methods: We conducted a single institutional retrospective analysis of all PHL patients (pts) diagnosed from 2000-2021 with a biopsy-proven liver lesion without other lymphomatous solid organ involvement, except for concurrently diagnosed splenic lymphomas. Subgroup analysis was performed for diffuse large B-cell lymphoma (DLBCL) and indolent lymphomas, which included marginal zone (MZL), follicular (FL), and low-grade B-cell lymphoma (BCL), NOS. Univariable (UVA) and multivariable analysis (MVA) for overall survival (OS) was performed using the Cox proportional hazards model. A literature review was also conducted using key words "liver", "lymphoma", and "treatment" to identify all available reported cases of PHL. An institutional targeted sequencing database was queried to identify patients with PHL of DLBCL histology. Results: We identified 30 PHL pts within the institutional cohort and 192 pts from comprehensive literature review. Sixteen patients were male (53%), and 25 (83%) were ECOG 0. Twenty five (83%) were Lugano Stage I, 3 (10%) were Stage III, and 2 (7%) were Stage IV. Six (20%) patients had bulky disease and 3 (10%) had nodal involvement. Systemic therapy was the most common treatment modality with 20 patients (67%), and 4 patients (13%) each received surgery, radiation and observation in our institutional cohort. In the paired literature review, 96 patients (50%) received systemic therapy, 69 (36%) underwent surgery, 10 (5%) received radiation and 11 (6%) underwent observation. Seventeen (57%) of patients were alive and 5 (17%) lost to follow-up within our institutional cohort, compared with 97 patients (51%) alive and 3 (2%) lost to follow-up. Median survival in our cohort was 6 years, compared with 2 years among the literature review cohort. Subgroup analysis of DLBCL included 15 pts (Table 1). On MVA for OS, only ECOG score (p=0.02) and Lugano stage (p=0.04) remained significant. Subgroup analysis of the indolent lymphoma group included 9 pts (Figure 1). On MVA for OS, only age remained significant. Six DLBCL patients with available targeted sequencing data were identified, with 4 mutations mutated more than once: TP53 (50%), MEF2B (33%), P2RY8 (33%), and IRF8 (33%). Pathway mapping of genetic mutations was notable for alterations in cell cycle pathway genes TP53 and ATM (17%). No other pathways had greater than one genetic alteration. Conclusion: PHLs are a rare subtype of NHL without clear treatment consensus. Primary hepatic DLBCL is predominantly treated with chemotherapy in both our institutional experience and as reported in the literature, with reasonable disease control. Importantly, indolent PHL patients in the institutional cohort have been treated with various modalities including low-dose radiotherapy, which appears to achieve comparable disease control. However radiotherapy was not utilized as a modality for indolent PHL within the literature review. Therefore, this is the first report of the use of low-dose radiotherapy for treatment of indolent liver lymphomas. Our RT data is limited by short follow-up duration of RT pts compared to pts who received chemotherapy, surgery or observation. However, our results are encouraging for the consideration of low-dose radiotherapy as a management option for appropriate patients with indolent PHL. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
火重火完成签到 ,获得积分10
刚刚
aaa完成签到,获得积分10
1秒前
SY15732023811完成签到 ,获得积分10
1秒前
QHS完成签到,获得积分10
2秒前
2秒前
燕燕完成签到,获得积分10
2秒前
hsssy完成签到,获得积分10
4秒前
4秒前
5秒前
十二完成签到,获得积分10
6秒前
情绪稳定完成签到 ,获得积分10
7秒前
忘想完成签到,获得积分10
7秒前
wushengdeyu完成签到 ,获得积分10
7秒前
核桃发布了新的文献求助10
9秒前
9秒前
丫丫完成签到,获得积分10
9秒前
YY完成签到,获得积分10
10秒前
10秒前
偷偷吃块肉完成签到,获得积分10
10秒前
芝芝完成签到 ,获得积分10
10秒前
北月南弦完成签到 ,获得积分10
11秒前
13秒前
13秒前
hh完成签到,获得积分10
14秒前
Geshup完成签到,获得积分10
15秒前
lyl完成签到 ,获得积分10
15秒前
可靠的大侠完成签到 ,获得积分10
16秒前
16秒前
17秒前
赤川川川完成签到 ,获得积分10
18秒前
Sugar完成签到,获得积分10
18秒前
何遇完成签到,获得积分10
18秒前
有趣的银完成签到,获得积分10
19秒前
elsa嘻嘻完成签到 ,获得积分10
19秒前
20秒前
1234@完成签到 ,获得积分10
20秒前
ppp发布了新的文献求助10
20秒前
20秒前
zjw完成签到,获得积分10
20秒前
舒心明杰完成签到,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166653
求助须知:如何正确求助?哪些是违规求助? 9559595
关于积分的说明 21751026
捐赠科研通 7757480
什么是DOI,文献DOI怎么找? 3429172
关于科研通互助平台的介绍 2553536
邀请新用户注册赠送积分活动 2473931